|Zeolite-based hemostat QuikClot releases calcium into blood and promotes blood coagulation in vitro.|
|Jump to Full Text|
|PMID: 23334236 Owner: NLM Status: MEDLINE|
|AIM: To examine the changes in electrolyte concentrations after addition of zeolite-based hemostat QuikClot in blood and the effects of zeolite on blood coagulation in vitro.
METHODS: Fresh blood was taken from healthy adult volunteers and sheep, and the electrolyte concentrations in blood were measured using a blood electrolyte analyzer. Zeolite Saline Solution (ZSS) was prepared by addition of 2 g zeolite to 0.9% NaCl solution (4, 8, or 16 mL). The electrolytes in ZSS were measured using inductively coupled plasma atomic emission spectroscopy. The prothrombin time (PT) and activated partial thromboplastin time (APTT) of blood were measured using the test tube method. The activated clotting time (ACT) and clotting rate (CR) of blood were measured with Sonoclot Coagulation and Platelet Function Analyzer.
RESULTS: Addition of zeolite (50 and 100 mg) in 2 mL human blood significantly increased Ca(2+) concentration, while Na(+) and K(+) concentrations were significantly decreased. Addition of zeolite (50 and 100 mg) in 0.9% NaCl solution (2 mL) caused similar changes in Ca(2+) and Na(+) concentrations. Si(4+) (0.2434 g/L) and Al(3+) (0.2575 g/L) were detected in ZSS (2 g/8 mL). Addition of ZSS in sheep blood shortened APTT in a concentration dependent manner, without changing PT. ZSS or aqueous solution of CaCl2 that contained Ca(2+) concentration identical to that of ZSS significantly shortened ACT in human blood without significantly changing CR, and the effect of ZSS on ACT was not significantly different from that of CaCl2.
CONCLUSION: Zeolite releases Ca(2+) into blood, thus accelerating the intrinsic pathway of blood coagulation and shortening the clot formation time.
|Jing Li; Wei Cao; Xiao-xing Lv; Li Jiang; Yue-jun Li; Wang-zhou Li; Shao-zong Chen; Xue-yong Li|
Related Documents :
|23493096 - Correlation between "abo" blood group phenotypes and periodontal disease: prevalence in...
173616 - Colonic blood flow in cat and man as analyzed by an inert gas washout technique.
21339246 - New prototype of femoral arterial smartcannula with anterograd and retrograde flow.
10371126 - Influence of different routes of flush perfusion on the distribution of lung preservati...
16723156 - High dose of intravenously given glucocorticosteroids decrease il-8 production by monoc...
2741746 - Time course of the blood-arterial wall barrier disruption following experimental subara...
|Type: In Vitro; Journal Article Date: 2013-01-21|
|Title: Acta pharmacologica Sinica Volume: 34 ISSN: 1745-7254 ISO Abbreviation: Acta Pharmacol. Sin. Publication Date: 2013 Mar|
|Created Date: 2013-03-05 Completed Date: 2013-12-27 Revised Date: 2014-10-01|
Medline Journal Info:
|Nlm Unique ID: 100956087 Medline TA: Acta Pharmacol Sin Country: United States|
|Languages: eng Pagination: 367-72 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Blood Coagulation / drug effects*
Blood Coagulation Tests
Calcium / blood*
Dose-Response Relationship, Drug
Electrolytes / blood*
Hemostatics / adverse effects, pharmacology*
Zeolites / adverse effects, pharmacology*
|0/Electrolytes; 0/Hemostatics; 0/Solutions; 1318-02-1/Zeolites; SY7Q814VUP/Calcium|
Journal ID (nlm-ta): Acta Pharmacol Sin
Journal ID (iso-abbrev): Acta Pharmacol. Sin
Publisher: Nature Publishing Group
Copyright © 2013 CPS and SIMM
Received Day: 02 Month: 07 Year: 2012
Accepted Day: 18 Month: 10 Year: 2012
Print publication date: Month: 03 Year: 2013
Electronic publication date: Day: 21 Month: 01 Year: 2013
Volume: 34 Issue: 3
First Page: 367 Last Page: 372
PubMed Id: 23334236
Publisher Item Identifier: aps2012159
|Zeolite-based hemostat QuikClot releases calcium into blood and promotes blood coagulation in vitro|
1Department of Burns and Plastic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi-an 710038, China
2Department of Interventional Radiology, Tangdu Hospital, the Fourth Military Medical University, Xi-an 710038, China
#These authors contributed equally to this work.
The zeolite-based hemostat QuikClot (QC) is a promising hemostatic agent that has been approved by the Food and Drug Administration (FDA) for the treatment of uncontrolled life-threatening hemorrhage. Zeolite exhibits distinct advantages in stability, accessibility and cost efficiency with no biological toxicity or risk of disease transmission. Animal studies have demonstrated the efficacy of zeolite in the stabilization of severe arterial hemorrhage1 and diffuse, long-term bleeding from lethal liver injuries2,3. The life-saving properties of QC have been confirmed under combat conditions in soldiers with uncontrolled bleeding4,5. QC has been used in civilian emergency settings because of its clinical value and treatment advantages.
However, several issues have emerged from the medical use of QC. First, zeolite produces an exothermic reaction when it comes into contact with blood, and the dramatic temperature increase damages tissues and causes injury6. Second, the agent is difficult to completely remove from the wound following application and may lead to the formation of inflammatory granulomas or abscesses because of foreign body reactions7. The current instructions for QC use are limited to the treatment of external sources of life-threatening hemorrhage that are uncontrollable by all other clinical means. These problems may be resolved by modification of the material properties of QC: for example, by altering the composition or structure of the material to enhance its hemostatic efficacy and reduce its side effects8,9. However, the mechanism of action underlying the hemostatic effect of zeolite and its interaction with blood are not clear. Therefore, the progress of structure modification has been limited.
Zeolite is thought to rapidly absorb water in a non-chemical reaction at the site of bleeding, which is thought to effectively concentrate platelets and clotting factors, promoting coagulation4,5. However, experimental evidence of this non-chemical reaction is lacking. Ostomel et al demonstrated that an Ag-exchanged zeolite hemostat released less heat upon hydration than the parent material, but the hemostatic efficacy of the modified material was reduced. The authors suggested that the accelerated coagulation response was due to multiple factors, including plasma metabolite concentration, contact activation of the blood-clotting cascade, and the thermal warming of the injured tissue8, but further research is required to verify these hypotheses.
Few research has been conducted on the release of ingredients from this hemostatic agent into the blood and the effects of these materials on the hemostatic process. Our study identified zeolite-induced changes in blood electrolytes and blood coagulation in vitro.
Fresh blood (8 mL) was extracted from the ulnar vein of healthy adult volunteers in a fasting state (males aged 18–20 years, n=8) in the morning. Two milliliters of each blood specimen was immediately infused into three test tubes. The tubes were mixed with 0 mg (control group), 50 mg or 100 mg of QC (QuikClot, Z-Medica, Newington, CT, USA) and gently shaken for 1 min. Each tube was maintained in a stationary position until the serum had separated out, and the serum was then collected for measuring. Electrolyte levels in the serum, such as those of Na+, K+, Ca2+, and Cl−, were measured using a blood electrolyte analyzer (BEA) (XD685, Xun-da Research Equipment Corporation, Shanghai, China).
The same experiments were performed in 2 mL of a 0.9% NaCl solution (preheated to 37 °C). Electrolyte concentrations were measured using a BEA.
QC (2 g) was added to 8 mL of a 0.9% NaCl solution (preheated to 37 °C), and the mixture was immediately vortexed for 1 min. The tube remained stationary for 10 min, and the supernatant was collected for sampling (zeolite saline solution, ZSS). QC (2 g) was added to 8 mL of deionized water in accordance with the above procedures, and the supernatant was collected for use as a control (zeolite deionized water solution, ZDWS). The contents of the saline solution (SS), ZSS, deionized water solution (DWS) and ZDWS were detected using inductively coupled plasma atomic emission spectroscopy (ICP-AES) (Optima 5300DV type, Perkin-Elmer Corporation, MA, USA).
The aforementioned tests demonstrated that zeolite altered the electrolyte concentrations in both the blood and a saline solution. In the experiment outlined below, ZSS was prepared as a test sample to simulate zeolite-induced electrolyte changes in the blood serum and investigate the effects of zeolite on blood coagulation.
Three ZSS samples were prepared: in the first sample, ZSS1 group, 2 g of QC was immersed in 4 mL of a saline solution; in the second sample, ZSS2 group, 2 g of QC was immersed in 8 mL of a saline solution; and in the third sample, ZSS3 group, 2 g of QC was immersed in 16 mL of a saline solution. The 0.9% saline solution was preheated to 37 °C in a test tube. The tube was vortexed for 1 min after the addition of QC to fully mix the solution. The tube remained stationary for 10 min, after which time the supernatant was collected for sampling.
Eight healthy adult sheep were provided by the Experimental Animal Center of the Fourth Military Medical University (qualified permit number: 07-009) and fed a standard diet. All sheep were observed for at least 1 week to ensure that the animals were free of any drugs or chemicals that might affect coagulation activity. Fresh blood (10 mL) was extracted from the external jugular veins of the animals, and the samples were immediately mixed with 3.8% sodium citrate (anticoagulant) with a volume ratio of 9:1. The blood was centrifuged at 3000 rounds per minute for 10 min to obtain approximately 5 mL of platelet-poor plasma (PPP) for use as a blood specimen. Eight blood specimens were prepared, and all specimens were tested within 1 h of preparation. The Laboratory Animal Care and Use Committee at the Fourth Military Medical University (Xi-an, China) approved this study.
The Zhongqin Shidi Scientific Instruments Corporation (Beijing) provided all reagents. All reagents, aqueous CaCl2 (25 mmol/L), saline solution and ZSS were preheated to 37 °C. Ten test tubes were prepared for the testing of each blood specimen. First, 100 μL of PPP was added to each tube. The PT or APTT reagents (100 μL) were added and mixed with the PPP by gentle shaking of the tube. The tubes were warmed to 37 °C in a water bath for 3 min and randomly assigned to one of five experimental groups (ZSS1, ZSS2, ZSS3, saline and control group; 2 tubes/group). ZSS1, ZSS2, ZSS3 and saline (20 μL of each) were then added to the test tubes, which remained stationary for 20 s. No solutions were added to the test tube in the control group. Aqueous CaCl2 (100 μL) was added to every test tube, and the technician quantified the thrombus formation time immediately. Two samples were measured successively in each test, and the average was recorded as PT or APTT. A professional technician performed all procedures in accordance with standard protocols. The technician who conducted the trials was blinded to the samples until the study was complete.
A small amount of the ZSS/SS solution was added to fresh blood to examine the effect of the sample solution on blood coagulation. The ACT and CR were recorded using a Sonoclot Coagulation and Platelet Function Analyzer (Sonoclot Analyzer, DP-2951, Sienco, CO, USA), according to standard protocols.
ZSS was prepared by the addition of 2 g of QC to 8 mL of a saline solution, according to the previously described procedure. A 0.9% NaCl solution was prepared as outlined above (ie, SS).
Eight healthy adult volunteers (males aged 18–19 years old) were involved in this experiment. The cubital vein was punctured in the morning during a fasting state, and a catheter was implanted, using heparin as an anticoagulant. The heparin tube was closed prior to each blood sample extraction, and 5 mL of blood was extracted and discarded. A new syringe was used to extract a 1.5 mL blood specimen. Three blood specimens were extracted from each volunteer, and the samples were randomly assigned to the ZSS group, the SS group or the control group. The interval between two samplings (ie, the time for completion of one testing) was approximately 5 min, and all of the procedures in each volunteer were completed in less than 30 min. All 8 specimens were included in each group.
A sample cuvette and the Sonoclot analyzer were preheated to 37 °C. Either ZSS or SS (20 μL) was added to the cuvette (gbACT+™ Kit, Sienco, USA), along with 340 μL of a blood specimen. For the control group, 360 μL of a blood specimen was added directly to the cuvette. The instrument automatically mixed the blood solutions, and the ACT and CR were recorded.
The concentration of Ca2+ in ZSS (which was prepared as described in the previous experiment) was 1.0610 g/L (26.5 mmol/L), as measured using ICP. An aqueous solution of 0.29% CaCl2, with a Ca2+ concentration that was identical to that of ZSS, was prepared.
Either ZSS or CaCl2 (20 μL) was added to the cuvette (gbACT+™ Kit, Sienco, CO, USA), and 340 μL of the blood specimen was added. A blood specimen (360 μL) was added directly to the cuvette in the control group. The instrument automatically mixed the blood solutions, and the ACT and CR were recorded.
All data are presented as mean±SEM. The SPSS 11.5 statistical software program (SPSS/Windows, SPSS Inc, Chicago, IL, USA) was used for inter-group comparisons. Analysis of variance was used to examine differences between the groups. The LSD t-test was used to make multiple comparisons between groups. Significance was defined as P<0.05.
The Ca2+ concentration increased in the blood after the addition of QC, but the Na+ and K+ concentrations decreased. The Ca2+ concentrations were 3.49±0.25 mmol/L (50 mg QC group) and 3.94±0.49 mmol/L (100 mg QC group), which were much higher than the Ca2+ concentrations in the control group (1.19±0.03 mmol/L) (P<0.05). However, the Na+ and K+ concentrations were significantly lower (P<0.05) in the 100 mg and 50 mg QC groups than that in the control group. These alterations were dose-dependent. The Ca2+concentration was higher (P=0.016) in the 100 mg QC group than that in the 50 mg QC group, but the Na+concentration was lower (P=0.037) in the 100 mg QC group than that in the 50 mg QC group. No differences in pH or Cl− concentration were observed between the three groups (Table 1).
Electrolyte concentrations were altered in the saline solution after the addition of zeolite. No Ca2+ was detected in the saline solution without QC, but the Ca2+ concentrations in the 50 mg QC and 100 mg QC groups were 0.80±0.02 mmol/L and 2.07±0.33 mmol/L, respectively. The Na+ concentrations in the 50 mg QC (147.48±0.21 mmol/L) and 100 mg QC groups (145.15±0.56 mmol/L) were significantly lower (P<0.05) than the Na+ concentrations in the control group (149.10±0.06 mmol/L). Significant differences in the Ca2+ and Na+ concentrations were observed between the 50 mg QC and 100 mg QC groups (P<0.05). No differences in the pH and Cl− concentrations were observed between the three groups (Table 2).
None of the studied components was detected in DWS. Minute amounts of Si4+ (0.1389 g/L), Al3+ (0.1318 g/L), Na+ (0.0764 g/L) and Ca2+ (0.0665 g/L) were detected in ZDWS. No elements, other than Na+ and Cl−, were detected in SS. Na+ (2.6870 g/L), Ca2+ (1.0610 g/L), Si4+ (0.2434 g/L) and Al3+ (0.2575 g/L) were detected in ZSS. The ratio of Si4+ to Al3+ in ZSS and ZDWS was approximately equal to 1. The Si4+ and Al3+ concentrations in ZSS were not more than twice the corresponding concentrations in ZDWS. However, the Ca2+ concentration in ZSS was more than 15 times the Ca2+ concentration in ZDWS (Table 3).
APTT is commonly used for the evaluation of the intrinsic pathway of blood coagulation in the clinic. Our results demonstrated that the APTTs were 25.16±4.03 s (ZSS1 group), 28.51±2.47 s (ZSS2 group) and 32.65±2.12 s (ZSS3 group). The APTTs in the ZSS1 and ZSS2 groups were shorter (P<0.05) than those in the ZSS3 group. However, all APTTs were significantly shorter (P<0.05) than those in the SS (41.53±3.37 s) and control groups (40.94±3.09 s). The APTT for the SS group was not significantly different from that of the control group. No difference in PT was observed between the groups (Table 4).
The average ACT for the ZSS group (106.38±18.10 s) was significantly shorter (P<0.05) than that of the control group (178.88±22.39 s). The ACT of the SS group was not significantly different from that of the control group. No differences in the CR were observed between the three groups (Table 5).
The average ACTs for the ZSS and CaCl2 groups were 103.14±19.61 s and 112.13±20.40 s, respectively. These ACTs were all significantly shorter (P<0.05) than the ACTs in the control group (163.47±17.42 s). The ACT for the ZSS group was not significantly different (P=0.47) from that of the CaCl2 group. No differences in the CR were observed between the three groups (Table 6).
The active component of QC is zeolite linde type 5A8. Zeolite 5A has an empirical formula of Na0.4Ca5.8(SiO2)12(AlO2)12·27H2O when fully hydrated, and the ratio of Si:Al is equal to 1. Low concentrations of Si4+, Al3+, Na+, and Ca2+ were detected in ZDWS by using ICP-AES. These elements were derived from zeolite because ZDWS is composed only of deionized water. Similarly, the detected Ca2+ in ZSS and the increase in the amount of Ca2+ detected in the blood were also derived from zeolite.
Generally, the constituents of a solute escape into an aqueous solution in one of two ways: physical dissolution or chemical reaction. The increase in the Si4+, Al3+, Na+, and Ca2+ concentrations in ZDWS must have, therefore, been derived from the dissolution of a small portion of zeolite because deionized water does not chemically react with zeolite. The Al3+, Si4+, and Ca2+ concentrations were higher in ZSS than those in ZDWS, and the Na+ concentration was lower. These changes were due to a cation exchange reaction between the zeolite and the NaCl solution.
Cation exchange is a fundamental chemical property of zeolite. A unit cell of zeolite linde type 5A is built from 12 silica and 12 alumina tetrahedral molecules that are bonded through shared oxygen atoms. The silicon in the silicon-oxygen tetrahedron was a quadrivalent cation, and the oxygen was a monovalent anion. Therefore, the tetrahedron was charge neutralized. The aluminum in the aluminum-oxygen tetrahedron was a trivalent cation. Therefore, the tetrahedron was negatively charged. Zeolite 5A usually absorbs metal ions, such as Na+, Ca2+ and Mg2+, in the open porous internal space to achieve a neutral charge. However, this combination is relatively weak, and the absorbed ions are readily exchanged with metal ions in solution. The cation exchange reaction is affected by several conditions, such as the metal ion concentration in the solution and the reaction temperature.
The addition of QC to either the blood or a 0.9% NaCl solution causes the release of the Ca2+ that is contained in zeolite into the blood or the solution and its replacement with Na+ and K+. This exchange may explain the increase in Ca2+ concentration and the decrease in Na+ and K+ concentrations in the blood and the NaCl solution following the addition of QC. This mechanism may also explain the absence of significant changes in Cl- concentration and pH. The Si4+ and Al3+ concentrations in ZSS were approximately two times higher than the concentrations in ZDWS. However, the Ca2+ concentration in ZSS was approximately sixteen times the concentration in ZDWS, and the Na+ concentration was significantly decreased. We inferred that Si4+ and Al3+ were released through the physical dissolution of a small amount of zeolite in ZSS, which was similar to the mechanism that occurred in ZDWS, but that Ca2+ was primarily released through a cation exchange reaction.
Our results demonstrated for the first time that the Ca2+ in zeolite is released into the blood and into a NaCl solution upon contact, as a result of a cation exchange reaction. This result provided the basis for the use of ZSS in further examinations of the impact of electrolyte changes on blood coagulation.
Blood clotting after vascular injury is a complex process that involves blood vessels, platelets, coagulation factors and the interaction of these factors. PT and APTT are the most commonly used indicators for the clinical evaluation of the extrinsic and intrinsic pathways of blood coagulation, respectively, according to the classical coagulation cascade model10.
We demonstrated that the APTT was shortened in all three of the ZSS groups using the test tube method, which suggested that ZSS accelerated the intrinsic pathway of blood coagulation. These results may be due to increased Ca2+ concentrations in ZSS. We assumed that the increase in Ca2+ concentration in ZSS would speed up the intrinsic pathway of blood coagulation by promoting the interaction of coagulating proteins. However, this hypothesis requires further investigation.
The Sonoclot analyzer is the most advanced instrument for the in vitro measurement of coagulation and platelet function in whole blood. This method provides accurate data on the entire hemostasis process, including coagulation, fibrin gel formation, clot retraction, and fibrinolysis. Therefore, this technique is used in a wide range of clinical and research applications, including cardiovascular surgery, liver transplant surgery, obstetrics, coagulation labs, hypercoagulable screening, and trauma applications.
Each Sonoclot analysis generates a qualitative graph, known as the Sonoclot Signature, as well as quantitative results on clot formation time (activated clotting time – onset, ACT) and the rate of fibrin polymerization (clot rate, CR). The ACT represents the time that the test sample remains a liquid. Fibrinogen is converted to fibrin monomers once thrombin forms in the test sample, and these monomers spontaneously polymerize to form a fibrin gel. The clot rate (CR) represents the rate of fibrin polymerization.
The ACT was significantly shorter in the ZSS group than that in the control group, but the CR was unchanged. These results suggested that ZSS accelerates the coagulation cascade mainly by increasing the rate of initial fibrin formation. However, fibrin polymerization was not affected. The previous experiment demonstrated that ZSS shortened the APTT. The mechanism underlying the shortened ACT may be attributed to the accelerating effect of ZSS on the intrinsic coagulation pathway.
We compared the effects of ZSS and an aqueous CaCl2 solution containing the same concentration of Ca2+ as the ZSS on the ACT and CR, to further examine whether the above effects of ZSS were related to decreases in Na+, K+, or other components, such as Si4+ and Al3+. The results demonstrated that there were no differences in the ACT and CR between the two groups. Therefore, the increase in Ca2+ may be the key factor for the procoagulant effects of ZSS.
Our study is the first to report the use of the Sonoclot analyzer for the evaluation of ZSS-induced blood clot formation. Our method exhibits some advantages. First, the use of fresh whole blood as a specimen precluded interference from the addition of anticoagulants or from blood separation. Therefore, the use of fresh whole blood more objectively revealed QC's blood coagulation function. Second, the clotting parameters ACT and CR exhibited dynamic changes in the blood coagulation process, which contributed to the analysis of the primary hemostatic effects of zeolite. Third, this method was rapid and simple to use, and the results were quantitative and reliable. The Sonoclot analyzer may be a reliable ancillary means for the investigation of the mechanisms of hemostatic agents and the analysis of hemostatic efficacy in vitro.
Therefore, these results suggest that not only the physical properties, such as the absorption of water and the concentration of coagulating factors, but also the chemical composition, especially the Ca2+ concentration, play important roles in the procoagulant actions of zeolites. These mechanisms may partially explain the results of Ostomel et al's study, in which the exchange of Ca2+ with Ag+ in a zeolite hemostatic agent reduced the heat of hydration, but impaired hemostatic efficacy8. This feature may be especially valuable for cases that are complicated by a Ca2+ deficiency-induced coagulopathy, such as patients who endure excessive bleeding. Our results also provide a basis for the further improvement of zeolite agents via alterations in chemical composition.
The limitations of this study include the limited group sizes that were used to explore zeolite-induced electrolyte changes in the blood and the effect of zeolite on clot formation. The relationship between zeolite dose and blood coagulation is not clear, and the impact of Ca2+ dose on zeolite-induced hemostasis requires further study.
In summary, zeolite released Ca2+ and absorbed Na+ and K+ upon contact with the blood via a cation exchange reaction. The increase in Ca2+shortened both the APTT and clot formation time in vitro. Cation exchange is an important mechanism of action underlying the hemostatic effect of zeolite.
Shao-zong CHEN and Xue-yong LI designed the research; Jing LI performed the research and wrote the manuscript; Wei CAO participated in the experiments; Xiao-xing LV analyzed the data; Li JIANG contributed new analytical tools and reagents; Yue-jun LI supervised the experiments; and Wang-zhou LI was responsible for revising the manuscript.
We would like to acknowledge the invaluable guidance and support provided by Qi-bing MEI, PhD (Department of Pharmacology, Fourth Military Medical University) and Dr Shu-jun HAN, MD (Department of Anesthesiology, General Hospital of Armed Police Forces). We also gratefully acknowledge the superb technical assistance provided by Ping HUANG (Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University).
|Alam HB,Chen Z,Jaskille A,Querol RI,Koustova E,Inocencio R,et al. Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swineJ TraumaYear: 2004569748315179235|
|Pusateri AE,Delgado AV,Dick EJ Jr,Martinez RS,Holcomb JB,Ryan KL. Application of a granular mineral-based hemostatic agent (QuikClot) to reduce blood loss after grade V liver injury in swineJ TraumaYear: 2004575556215454802|
|Inaba K,Rhee P,Teixeira PG,Barmparas G,Putty B,Branco BC,et al. Intracorporeal use of advanced local hemostatics in a damage control swine model of grade iv liver injuryJ TraumaYear: 2011711312822002611|
|Rhee P,Brown C,Martin M,Salim A,Plurad D,Green D,et al. QuikClot use in trauma for hemorrhage control: case series of 103 documented usesJ TraumaYear: 2008641093918404080|
|Alam HB,Burris D,DaCorta JA,Rhee P. Hemorrhage control in the battlefield: role of new hemostatic agentsMil MedYear: 200517063915724857|
|Wright JK,Kalns J,Wolf EA,Traweek F,Schwarz S,Loeffler CK,et al. Thermal injury resulting from application of a granular mineral hemostatic agentJ TraumaYear: 2004572243015345965|
|Wright FL,Hua HT,Velmahos G,Thoman D. Intracopreal use of the hemostatic agent QuickClot in a coagulopathic patient with combined thoracoabdominal penetrating traumaJ TraumaYear: 200456205814749593|
|Ostomel TA,Stoimenov PK,Holden PA,Alam HB,Stucky GD. Host-guest composites for induced hemostasis and therapeutic healing in traumatic injuriesJ Thromb ThrombolysisYear: 200622556716786234|
|Mortazavi SM,Atefi A,Roshan-Shomal P,Raadpey N,Mortazavi G. Development of a novel mineral based haemostatic agent consisting of a combination of bentonite and zeolite mineralsJ Ayub Med Coll AbbottabadYear: 2009213720364729|
|Hoffman R,Benz EJ jr,Shattil SJ. Hematology: Basic principles and practice, 4th ed. Philadelphia, PA: Elsevier, Churchill Livingstone; Year: 2005|
Keywords: hemostatics, QuikClot, zeolites, electrolytes, calcium, blood coagulation, prothrombin time, activated partial thromboplastin time, activated clotting time, clotting rate.
Previous Document: Co-delivery of ccl19 gene enhances anti-caries DNA vaccine pCIA-P immunogenicity in mice by increasi...
Next Document: Design, synthesis and biological evaluation of bivalent ligands against A(1)-D(1) receptor heteromer...